Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: brain ; tumor ; evaluation ; Germany ; imaging ; TUMORS ; TIME ; PATIENT ; primary ; BODY-WEIGHT ; CONTRAST ; INJECTION ; MR ; ACQUISITION ; EFFICACY ; metastases ; PARAMETERS ; STATISTICAL-ANALYSIS ; MORPHOLOGY ; SAFETY ; CENTRAL-NERVOUS-SYSTEM ; CONTRAST AGENTS ; DOUBLE-BLIND ; GADOBENATE-DIMEGLUMINE ; GADODIAMIDE INJECTION ; GADOPENTETATE DIMEGLUMINE ; INTRACRANIAL METASTASES ; gadobenate dimeglumine ; MR imaging ; VASCULARIZATION ; GLIOMAS ; ENHANCED MRI ; brain neoplasms,MR,gadolinium,magnetic resonance (MR),contrast media ; HIGH-DOSE GADOTERIDOL ; MAGNEVIST GD-DTPA
    Abstract: PURPOSE: To evaluate the safety of and compare the enhancement characteristics of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) with those of a standard gadolinium chelate (gadopentetate dimeglumine, Magnevist; Schering, Berlin, Germany) in primary and secondary brain tumors on the basis of qualitative and quantitative parameters, on an intraindiviual basis.MATERIALS AND METHODS: Twenty-seven patients with either high-grade glioma or metastases were enrolled in a bicentric intraindividual crossover study to compare lesion enhancement with doses of 0.1 mmol per kilogram of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine. MR imaging was performed before injection (T1-weighted spin-echo [SE] and T2-weighted fast SE acquisitions) and at 1, 3, 5, 7, 9, and 16 minutes after injection (T1-weighted SE acquisitions). Qualitative assessment was performed by blinded off-site readers (for 22 patients) and on-site investigators (for 24 patients) in terms of global contrast enhancement, lesion-to-brain contrast, lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference. Additional quantitative assessment with region-of-interest analysis was performed by off-site readers alone. Statistical analysis of qualitative data was performed with the Wilcoxon signed rank test, whereas a nonparametric approach was adopted for analysis of quantitative data.RESULTS: Significant (P 〈 .05) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on-site for the global assessment of contrast enhancement. For off-site readers I and 2 and the on-site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, and four patients; and equality was found in five, one, and four patients). Similar preference for gadobenate dimeglumine was noted by off-site readers and on-site investigators for lesion-to-brain contrast and all other qualitative parameters. Off-site quantitative evaluation revealed significantly (P 〈 .05) superior enhancement for gadobenate dimeglumine compared with that for gadopentetate dimeglumine at all time points from 3 minutes after injection.CONCLUSION: Significantly superior contrast enhancement of intraaxial enhancing brain tumors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/kg gadopentetate dimeglumine. (C) RSNA, 2004
    Type of Publication: Journal article published
    PubMed ID: 14695387
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...